We are live on ! Find out more
HEPA

Hepion Pharmaceuticals
HEPA

Delisted

HEPA was delisted on the 12th of May, 2025.

Back to rankings

3 hedge funds and large institutions have $8.61M invested in Hepion Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% less capital invested

Capital invested by funds: $15.3M → $8.61M (-$6.72M)

50% less funds holding

Funds holding: 6 → 3 (-3)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
3
Holders Change
-3
Holders Change %
-50%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$834K

Top Sellers

Rank Fund Capital Flow
1
TCIM
TIAA CREF Investment Management
New York
-$4.41M
2
EI
EAM Investors
California
-$3.4M
3
TA
Teachers Advisors
New York
-$1.82M
4
Russell Investments Group
Russell Investments Group
United Kingdom
-$72K
5
TSS
Two Sigma Securities
New York
-$18K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.63M +$834K +1 +33%
HighTower Advisors
2
HighTower Advisors
Illinois
$1.85M – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$626K – – –
Morgan Stanley
4
Morgan Stanley
New York
$493K – – –
JP Morgan Chase
5
JP Morgan Chase
New York
$354K – – –
PFS
6
Prospera Financial Services
Texas
$287K – – –
CS
7
Credit Suisse
Switzerland
$267K – – –
Barclays
8
Barclays
United Kingdom
$214K – – –
Northern Trust
9
Northern Trust
Illinois
$202K – – –
Bank of Montreal
10
Bank of Montreal
Ontario, Canada
$142K – – –
BlackRock
11
BlackRock
New York
$93K – – –
RA
12
RFG Advisory
Alabama
$65K – – –
BRWA
13
B. Riley Wealth Advisors
Florida
$46K – – –
Citadel Advisors
14
Citadel Advisors
Florida
$46K – – –
Bank of New York Mellon
15
Bank of New York Mellon
New York
$38K – – –
ISL
16
Ingalls & Snyder LLC
New York
$37K – – –
Cambridge Investment Research Advisors
17
Cambridge Investment Research Advisors
Iowa
$30K – – –
VKH
18
Virtu KCG Holdings
New York
$30K – – –
AIM
19
Acrospire Investment Management
Illinois
$29K – – –
LPL Financial
20
LPL Financial
California
$27K – – –
Goldman Sachs
21
Goldman Sachs
New York
$23K – – –
EWA
22
Exencial Wealth Advisors
Oklahoma
$19K – – –
FFA
23
First Foundation Advisors
California
$18K – – –
LWM
24
LBA Wealth Management
Florida
$14K – – –
Wells Fargo
25
Wells Fargo
California
$11K – – –
1
2

HEPA Hedge Fund Activity: Q1 2017 in Review

3 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2017, worth a combined $8.61M — down 44% from $15.3M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of HEPA and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was Vanguard Group, adding an estimated $834K. The largest seller was TIAA CREF Investment Management, exiting entirely with an estimated $4.41M sold.

  • 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2017, down from 6 in Q4 2016.
  • Funds reported $8.61M of Hepion Pharmaceuticals stock for Q1 2017, down 44% quarter-over-quarter.
  • 0 funds opened new Hepion Pharmaceuticals positions in Q1 2017 and 3 closed out, a net change of -3 holders.
  • The largest Hepion Pharmaceuticals buyer in Q1 2017 was Vanguard Group, an estimated $834K added.
  • The largest Hepion Pharmaceuticals seller in Q1 2017 was TIAA CREF Investment Management, an estimated $4.41M sold.

Based on aggregated 13F filings for Q1 2017.